

No. BPPI/DRUG/RC-116/2019, No. BPPI/DRUG/RC-156/2020,  
No. BPPI/DRUG/RC-159/2021

Dated: 17/06/2022

ORDER

Bureau of Pharma Public Sector Undertakings of India, New Delhi now PMBI had published tender No. BPPI/DRUG/RC-116/2019, No. BPPI/DRUG/RC-156/2020, No. BPPI/DRUG/RC-159/2021 dated 18.03.2021 through e-procurement system for supply of drugs for the year 2019-21, 2020-22 & 2021-23.

Whereas M/S Healthy Life Pharma Pvt. Ltd. (here after called as the firm) addressed at 401, Richa Plot No. B-29, New Link Road, Andheri West, Mumbai Maharashtra-400058 had participated in tender. The firm was awarded including DC- 144, 188, 1005 and 1042 by Bureau of Pharma Public Sector Undertakings of India, New Delhi now PMBI vide Letter of acceptance dated 24.01.2020 & 10.04.2020, 14.12.2020 & 26.02.2021 & 15.07.2021 for the period of 2 years as per tender provision. The firm was asked to supply the drugs within 45 days against purchase orders as per clause 19 (D) of tender document as per details below: -

Sr. no.	PO No.	Posting Date	Delivery Date	Item No.	Item/Service Description	PO QTY	Open Qnty
1	2102001726	09.07.21	23.08.21	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	300,000	300,000
2	2102002355	19.08.21	03.10.21	1042	Risperidone Tablets IP 4mg	50,000	50,000
3	2102001751	09.07.21	23.08.21	1042	Risperidone Tablets IP 4mg	20,000	20,000
4	2102003657	16.09.21	31.10.21	1005	Phenobarbitone Tablets IP 30mg	8,000	3,760
5	2102003957	26.10.21	10.12.21	188	Dried Aluminium Hydroxide 250mg, Magnesium Hydroxide 250mg and Activated Dimethicone 50mg Tablets	26,400	0
6	2102003956	26.10.21	10.12.21	188	Dried Aluminium Hydroxide 250mg, Magnesium Hydroxide 250mg and Activated Dimethicone 50mg Tablets	39,600	0

Whereas Pharmaceuticals & Medical Devices Bureau of India, New Delhi sent show cause notice vide reference No. BPPI/DRUG/RC-116/2019, No. BPPI/DRUG/RC-156/2020, No. BPPI/DRUG/RC-159/2021 to M/S Healthy Life Pharma Pvt. Ltd. through mail/DAK dated

20.01.20222 asking for explanation and Bureau of Pharma Public Sector Undertakings of India, New Delhi to the firm informing about provisions of the clause No. 19(G), 26(H), 27(A) and 27(E) of tender document with request to supply of goods.

- (i) **Consider bad performance for future dealings and disqualify your company from participating in the tender for the next 2 years.**
- (ii) **Recover 5% value of supply order from pending bills.**
- (iii) **Initiate blacklisting of your company.**
- (iv) **Forfeiture of Performance Security Deposit from Supplied Purchase orders.**

Whereas the firm replied after giving reminder on dated 02.02.2022 through mail dated 02.02.2022 against show cause notice wherein they have informed that due to Shortage of raw Material M/S Healthy Life Pharma Pvt. Ltd. was unable to supply but they have now procured Raw Material and all POs will be supplied soon but till now we have not received supply for DC-144 & 1042. Therefore 5% of total value of mentioned purchase orders Rs. 120787/- (Including 18% IGST) along with forfeiture of performance security deposit shall be recover as per tender term & conditions.

In view of above, the firm is debarred for a period of two (02) successive years to participate in the tender of **Pharmaceuticals & Medical Devices Bureau of India, New Delhi** for supply of *DC- 1042 Risperidone Tablets IP 4mg* from date of issuance of this order.

This order is without prejudice to the legal and criminal action to be taken if any, by Pharmaceuticals & Medical Devices Bureau of India, New Delhi in the matter.



Ravi Dadhich, DANICS  
Chief Executive Officer  
Pharmaceuticals & Medical Devices Bureau of India, New Delhi

Regd.  
To,  
M/S Healthy Life Pharma Pvt. Ltd.  
401, Richa Plot No. B-29,  
New Link Road, Andheri West  
Mumbai Maharashtra- 400058